Thermo Fisher Scientific Inc. $TMO Shares Sold by Terra Nova Asset Management LLC

Terra Nova Asset Management LLC lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 33.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 528 shares of the medical research company’s stock after selling 266 shares during the quarter. Terra Nova Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $214,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Prudential PLC boosted its position in Thermo Fisher Scientific by 25.0% in the 2nd quarter. Prudential PLC now owns 7,712 shares of the medical research company’s stock worth $3,127,000 after purchasing an additional 1,540 shares in the last quarter. Lionshead Wealth Management LLC raised its stake in shares of Thermo Fisher Scientific by 137.1% during the 2nd quarter. Lionshead Wealth Management LLC now owns 1,788 shares of the medical research company’s stock worth $726,000 after buying an additional 1,034 shares during the period. Quilter Plc lifted its holdings in Thermo Fisher Scientific by 15.0% during the second quarter. Quilter Plc now owns 276,111 shares of the medical research company’s stock valued at $111,952,000 after purchasing an additional 35,983 shares in the last quarter. Artisan Partners Limited Partnership purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $114,706,000. Finally, Empirical Finance LLC grew its holdings in shares of Thermo Fisher Scientific by 3.6% during the second quarter. Empirical Finance LLC now owns 13,915 shares of the medical research company’s stock worth $5,642,000 after buying an additional 489 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 0.5%

NYSE TMO opened at $573.39 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The firm has a market cap of $215.43 billion, a price-to-earnings ratio of 33.12, a PEG ratio of 3.27 and a beta of 0.82. The firm has a 50 day simple moving average of $533.28 and a 200-day simple moving average of $471.15. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period last year, the firm earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is 9.94%.

Thermo Fisher Scientific declared that its board has approved a stock repurchase program on Thursday, November 6th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

Several analysts have issued reports on TMO shares. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. UBS Group lifted their target price on Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research report on Thursday, October 23rd. Evercore ISI boosted their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Finally, Argus upped their price objective on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $601.65.

Insider Buying and Selling

In other news, COO Michel Lagarde sold 4,638 shares of the company’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $594.42, for a total transaction of $2,756,919.96. Following the completion of the transaction, the chief operating officer directly owned 23,480 shares of the company’s stock, valued at approximately $13,956,981.60. This represents a 16.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 51,845 shares of company stock worth $28,956,952. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.